Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Richmond Pharmacology early phase drug development update.
Dr Jorg Taubel discusses some of the steps taken at Richmond Pharmacology to ensure clinical trials can continue to operate at a high standard throughout the COVID-19 pandemic.
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.
View our latest peer-reviewed publications from a selection of our clinical trials.
Learn more about Richmond Pharmacology by viewing some of our videos.